Thermo Fishr Sci Stock Price, News & Analysis

Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per share, approved by its Board of Directors on July 7, 2022. The dividend is set to be paid on October 14, 2022, to shareholders on record as of September 15, 2022. With annual revenues around $40 billion, Thermo Fisher continues to support scientific progress through innovative technologies and services.

Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q2 2022 on Thursday, July 28, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss financial performance and future expectations.

The company reported an annual revenue of approximately $40 billion, supporting various scientific endeavors globally.

Relation Therapeutics has successfully raised $25 million in a seed financing round led by DCVC and Magnetic Ventures. The new capital will help expand its platform that integrates active-graph machine learning with single-cell analysis to accelerate drug discovery, targeting diseases with limited treatment options.

Dr. David Roblin and Dr. Lindsay Edwards have joined the company as CEO and CTO, respectively. The funding aims to enhance the understanding of disease biology and improve therapeutic outcomes.

Thermo Fisher Scientific (NYSE:TMO) has unveiled new mass spectrometry instruments, workflows, and software at the 70th ASMS Conference from June 5-9, 2022, in Minneapolis. These innovations aim to enhance analytical insights and accelerate biopharma development. Notable products include the Thermo Scientific Direct Mass Technology and the AccelerOme Automated Sample Preparation Platform, designed to improve reproducibility and detail in biotherapeutic analysis. Additionally, cross-industry collaboration with TransMIT GmbH aims to enhance spatial multi-omics applications.

Thermo Fisher Scientific (NYSE:TMO) released its annual Corporate Social Responsibility report, emphasizing progress in environmental, social, and governance (ESG) objectives. Key highlights include a 12% reduction in Scope 1 and 2 emissions since 2018, commitment to net-zero emissions by 2050, and an increase in spending with underrepresented businesses from $1.3 billion to $2.0 billion. The company also engaged over 100,000 students in STEM programs and logged 105,000 volunteer hours globally.

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per common share on May 18, 2022. The dividend will be payable on July 15, 2022, to shareholders of record as of June 15, 2022. The company, a leading name in serving science, reported an annual revenue of approximately $40 billion. Thermo Fisher aims to enhance health, safety, and environment through its extensive range of innovative technologies and services.

Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its CEO, Marc N. Casper, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. EDT. The presentation will be accessible via a webcast on the company's Investor Relations page. Thermo Fisher Scientific reported annual revenues of approximately $40 billion, focusing on making the world healthier, cleaner, and safer through innovative technologies and pharmaceutical services. For more details, visit www.thermofisher.com.

Thermo Fisher Scientific reported first-quarter 2022 revenue of $11.82 billion, achieving 19% growth year-over-year. The company's GAAP diluted EPS was $5.61, down from $5.88 in Q1 2021, while adjusted EPS rose to $7.25. The results highlighted 16% core organic growth and $1.68 billion from COVID-19 testing. The launch of innovative products and a 15-year collaboration with Moderna for mRNA vaccine manufacturing were key highlights. The company also repurchased $2.0 billion in stock and increased its dividend by 15%.